Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surrogate anti-mouse IL1RAP ADC
- Development stage
- Preclinical
- Lead developer
- Cantargia
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The surrogate anti-mouse IL1RAP ADC is a research-grade antibody-drug conjugate (ADC) developed by Cantargia AB in collaboration with AbbVie. It consists of a monoclonal antibody specific for murine Interleukin-1 receptor accessory protein (IL1RAP) conjugated to a maytansinoid cytotoxic payload via a cleavable linker. This surrogate molecule was designed to evaluate the safety and toxicity profile of IL1RAP-targeting ADCs in immunocompetent mouse models, as the primary clinical candidate is optimized for human and cynomolgus IL1RAP. IL1RAP is a co-receptor for IL-1, IL-33, and IL-36 signaling and is overexpressed on various tumor cells and within the tumor microenvironment, including cancer-associated fibroblasts and suppressive immune cells. The surrogate allows for the assessment of potential on-target, off-tumor toxicities in tissues where IL1RAP is endogenously expressed in mice.
- Other names
- anti-mouse IL1RAP ADC
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)
Beyond the preview
Go deeper on surrogate anti-mouse IL1RAP ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surrogate anti-mouse IL1RAP ADC.